These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


324 related items for PubMed ID: 8033373

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.
    Wallaschofski H, Kuwert T, Lohmann T.
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):171-4. PubMed ID: 15127319
    [Abstract] [Full Text] [Related]

  • 4. Assays of TSH-receptor antibodies in 576 patients with various thyroid disorders: their incidence, significance and clinical usefulness.
    Macchia E, Concetti R, Borgoni F, Cetani F, Fenzi GF, Pinchera A.
    Autoimmunity; 1989 Apr; 3(2):103-12. PubMed ID: 2577491
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.
    Nygaard B, Faber J, Veje A, Hegedüs L, Hansen JM.
    Thyroid; 1999 May; 9(5):477-81. PubMed ID: 10365679
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays.
    Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P.
    Clin Endocrinol (Oxf); 2001 Sep; 55(3):381-90. PubMed ID: 11589682
    [Abstract] [Full Text] [Related]

  • 9. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA, Daykin J, Holder R, Sheppard MC.
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
    Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O.
    Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease.
    Aizawa Y, Yoshida K, Kaise N, Kaise K, Fukazawa H, Kiso Y, Mori K, Sayama N, Kikuchi K, Abe K.
    Clin Endocrinol (Oxf); 1995 May; 42(5):517-22. PubMed ID: 7621571
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Relapses of hyperthyroidism in patients treated with radioiodine for nodular toxic goiter: relation to thyroid autoimmunity.
    Custro N, Ganci A, Scafidi V.
    J Endocrinol Invest; 2003 Feb; 26(2):106-10. PubMed ID: 12739735
    [Abstract] [Full Text] [Related]

  • 20. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE, Michanek AM, Holmberg EC, Fink M.
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 17.